Stockscreener 앱 받기
94.99
0.61%
0.58
전일 마감가:
$94.41
열려 있는:
$95.05
하루 거래량:
2.07M
Relative Volume:
1.67
시가총액:
$11.34B
수익:
$2.77B
순이익/손실:
$286.61M
주가수익비율:
40.42
EPS:
2.35
순현금흐름:
$524.11M
1주 성능:
+1.56%
1개월 성능:
+1.51%
6개월 성능:
-15.61%
1년 성능:
-11.64%
1일 변동 폭
$94.14
$95.69
1주일 범위
$92.78
$96.52
52주 변동 폭
$87.70
$129.50
퍼킨엘머 Stock (RVTY) Company Profile
명칭
Revvity Inc
전화
781-663-6900
주소
77 4TH AVENUE, WALTHAM
RVTY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
94.99 | 11.34B | 2.77B | 286.61M | 524.11M | 2.35 |
|
TMO
Thermo Fisher Scientific Inc
|
397.88 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
196.39 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
523.92 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.56 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
154.73 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
퍼킨엘머 Stock (RVTY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-01 | 업그레이드 | UBS | Neutral → Buy |
| 2025-01-10 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-10-15 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Equal Weight |
| 2024-07-08 | 개시 | Leerink Partners | Outperform |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-01-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-04 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-12-19 | 개시 | Wells Fargo | Equal Weight |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-07-19 | 개시 | Raymond James | Outperform |
| 2023-05-23 | 재개 | Goldman | Buy |
모두보기
퍼킨엘머 주식(RVTY)의 최신 뉴스
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
How To Trade (RVTY) - news.stocktradersdaily.com
Are Revvity, Inc.'s (NYSE:RVTY) Mixed Financials Driving The Negative Sentiment? - simplywall.st
Revvity introduces new IVD reference standards for monitoring oncology diagnostic testing workflows - SelectScience
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity at Goldman Sachs Conference: Diagnostics and Software Focus By Investing.com - Investing.com Canada
Revvity at Goldman Sachs Conference: Diagnostics and Software Focus - Investing.com
Transcript : Revvity, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
Revvity To Present At Goldman Sachs Global Healthcare Conference; Webcast At 8:00 AM ET - Nasdaq
Wellington Management Group LLP Has $743,000 Stock Holdings in Revvity, Inc. (NYSE:RVTY) - Defense World
(RVTY) Long Term Investment Analysis - news.stocktradersdaily.com
Revvity gets FDA nod for its automated tuberculosis test - MSN
4 Mass. Rulings You May Have Missed In May - Law360
Revvity (RVTY) Introduces New Mimix Standards for Improved IVD Testing | RVTY Stock News - GuruFocus
New Cancer Testing Standards from Revvity Promise More Accurate Diagnostic Results for Oncology Labs - Stock Titan
Insider Sell: Michelle Mcmurry-heath Sells 600 Shares of Revvity Inc (RVTY) - GuruFocus
Does The Market Have A Low Tolerance For Revvity, Inc.'s (NYSE:RVTY) Mixed Fundamentals? - Yahoo
Millennium Management LLC Trims Position in Revvity, Inc. (NYSE:RVTY) - Defense World
Shareholders in Revvity (NYSE:RVTY) are in the red if they invested three years ago - simplywall.st
Revvity Inc (RVTY) Shares Up 3.52% on May 27 - GuruFocus
Revvity, Inc. (NYSE:RVTY) Shares Purchased by Cetera Investment Advisers - Defense World
RVTY Stock Falls Despite the Latest Launch of Automated Instrument - MSN
Revvity (NYSE:RVTY) Cut to “Hold” at Wall Street Zen - Defense World
Zacks Research Forecasts Revvity’s Q1 Earnings (NYSE:RVTY) - Defense World
Revvity’s EUROIMMUN unveils new fully automated instrument for specialty testing - SelectScience
Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing - Technology Networks
Enhancing Laboratory Efficiency with Revvity's IDS i20™ Platform - Lab Manager
Is Wall Street Bullish or Bearish on Revvity Stock? - inkl
Is Wall Street Bullish Or Bearish On Revvity Stock? - Barchart.com
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlo - GuruFocus
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlook | RVTY Stock News - GuruFocus
Sustainable chemistry in India fueling growth with digital and AI innovation: Revvity Signals - Indian Chemical News
Ameriprise Financial Inc. Increases Stock Position in Revvity, Inc. (NYSE:RVTY) - Defense World
Revvity announces launch of new fully automated instrument for specialty testing - BioSpectrum India
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for S - GuruFocus
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing | RVTY Stock News - GuruFocus
Element Biosciences Welcomes Dr. Madhuri Hegde to its Board of Directors - Business Wire
Revvity Signals Software Inc. v. Cloud Software Group Inc. - Cornerstone Research
Revvity Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Global Preeclampsia Diagnostics Market to Exhibit Growth at a CAGR of ~4% by 2032 | DelveInsight - GlobeNewswire Inc.
Shareholders Will Be Pleased With The Quality of Revvity's (NYSE:RVTY) Earnings - Yahoo
Revvity at Bank of America 2025 Healthcare Conference: Navigating Tariffs and Growth - Investing.com India
Revvity To Present At Bank Of America Global Healthcare Conference 2025; Webcast At 12:20 PM ET - Nasdaq
Revvity beats quarterly estimates on steady demand for medical equipment - MSN
Repligen, Bruker, Agilent, Medpace, and Revvity Shares Skyrocket, What You Need To Know - Yahoo Finance
RVTY Q1 Earnings Call: Resilient Performance Amid Academic and Tariff Headwinds, Software and Diagnostics Shine - Yahoo Finance
Revvity: Despite Facing Multiple Headwinds, Shares Are A Buy (NYSE:RVTY) - Seeking Alpha
High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire
High Content Screening Market Global Forecasts 2025-2030 with Danaher, Revvity, BD, Carl Zeiss, Merck, and Thermo Fisher Scientific Dominating the $2.19 Billion Market - Yahoo Finance
Revvity joins peers Thermo Fisher, Danaher in tariff warning, maintains profit outlook - MSN
Revvity Announces Financial Results for the First Quarter of 2025 - ADVFN
퍼킨엘머 (RVTY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.19%
0.96%
자본화:
|
볼륨(24시간):